Boston Scientific (BSX) Panoramica del titolo
Boston Scientific Corporation sviluppa, produce e commercializza in tutto il mondo dispositivi medici per l'impiego in varie specialità di medicina interventistica. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
BSX ha superato i nostri controlli di rischio.
BSX Community Fair Values
Create NarrativeSee what 143 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$98.9
FV
56.0% sottovalutato sconto intrinseco9.80%
Revenue growth p.a.
495
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
18users have followed this narrative
Concorrenti di Boston Scientific Corporation
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$43.48 |
| Massimo di 52 settimane | US$109.50 |
| Minimo di 52 settimane | US$43.37 |
| Beta | 0.56 |
| Variazione di 1 mese | -10.00% |
| Variazione a 3 mesi | -30.71% |
| Variazione di 1 anno | -59.52% |
| Variazione a 3 anni | -18.79% |
| Variazione a 5 anni | -1.00% |
| Variazione dall'IPO | 915.59% |
Notizie e aggiornamenti recenti
Seeking Alpha • Jun 25
Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity
Summary Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins. BSX shares are undervalued below the high $50s to low $60s; rerating requires consistent execution and no further cuts to guidance. Read the full article on Seeking AlphaArticolo di analisi • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...Recent updates
Seeking Alpha • Jun 25
Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity
Summary Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins. BSX shares are undervalued below the high $50s to low $60s; rerating requires consistent execution and no further cuts to guidance. Read the full article on Seeking AlphaArticolo di analisi • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...
Aggiornamento della narrazione • Jun 16
BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations
Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.Aggiornamento della narrazione • Jun 01
BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations
Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.Aggiornamento della narrazione • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
Nuova narrazione • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.
Nuova narrazione • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.Aggiornamento della narrazione • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.Aggiornamento della narrazione • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.Aggiornamento della narrazione • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.Aggiornamento della narrazione • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
Nuova narrazione • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Aggiornamento della narrazione • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.Aggiornamento della narrazione • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.Aggiornamento della narrazione • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.Aggiornamento della narrazione • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.Aggiornamento della narrazione • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.Aggiornamento della narrazione • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.Articolo di analisi • Jul 21
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Jul 04
Returns At Boston Scientific (NYSE:BSX) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Seeking Alpha • Mar 18
Boston Scientific: Bright Future, Rather Pricey
Summary A diversified portfolio, strategic acquisitions, and aggressive R&D have driven Boston Scientific's recent revenue and EPS growth, outpacing peers like Abbott and Medtronic. Consequently, BSX stock is trading at a significant premium, reflecting high investor optimism. Intense competition along with regulatory and safety concerns also remain key challenges. While Boston's fundamentals suggest that double-digit earnings growth can be sustained, there may be little margin for error at the current stock price. I recommend a Hold at ~$97. Read the full article on Seeking AlphaRendimenti per gli azionisti
| BSX | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | -1.9% | 4.6% | 0.3% |
| 1Y | -59.5% | -21.2% | 19.9% |
Ritorno vs Industria: BSX ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -21.2 % nell'ultimo anno.
Rendimento vs Mercato: BSX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 19.9 % nell'ultimo anno.
Volatilità dei prezzi
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: BSX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di BSX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation sviluppa, produce e commercializza in tutto il mondo dispositivi medici per l'impiego in varie specialità di medicina interventistica. L'azienda opera in due segmenti, MedSurg e Cardiovascular. Offre dispositivi per la diagnosi e il trattamento di una serie di patologie gastrointestinali, come clip di risoluzione, sistemi di stent biliari, stent e sistemi di somministrazione potenziata di elettrocauteri, SpyGlass, cannocchiali monouso utilizzati per procedure diagnostiche e terapeutiche nel sistema pancreatico-biliare, nelle procedure di colangiopancreatografia retrograda endoscopica e duodenoscopi monouso, nonché prodotti per la chirurgia endoluminale e la prevenzione delle infezioni; dispositivi per il trattamento di patologie urologiche, tra cui stent ureterali, cateteri, cestelli, fili guida, disfunzioni urinarie e intestinali, guaine, palloncini, ureteroscopi flessibili digitali monouso, sistemi laser a olmio, impianti penieni, sfinteri urinari artificiali, sistemi laser e sistemi in idrogel; e dispositivi per il trattamento di disturbi neurologici del movimento e la gestione del dolore cronico, come sistemi di stimolazione del midollo spinale, ablazione a radiofrequenza, ablazione dei nervi intraossei e sistemi di stimolazione cerebrale profonda.
Boston Scientific Corporation Riepilogo dei fondamenti
| BSX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$65.74b |
| Utili (TTM) | US$3.57b |
| Ricavi(TTM) | US$20.61b |
18.1x
Rapporto P/E3.1x
Rapporto P/SBSX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| BSX Conto economico (TTM) | |
|---|---|
| Ricavi | US$20.61b |
| Costo del fatturato | US$6.40b |
| Profitto lordo | US$14.21b |
| Altre spese | US$10.65b |
| Utili | US$3.57b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Jul 29, 2026
| Utile per azione (EPS) | 2.40 |
| Margine lordo | 68.94% |
| Margine di profitto netto | 17.29% |
| Rapporto debito/patrimonio netto | 41.8% |
Come si è comportato BSX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/29 11:34 |
| Prezzo dell'azione a fine giornata | 2026/06/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Boston Scientific Corporation è coperta da 58 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |